Informed Prostate Cancer Patient Support

Variations in Medical Necessity Determinations Across Commercial Insurance Carriers for Prostate Cancer Procedures - International Journal of Radiation Oncology, Biology, Physics redjournal.org Variations in Medical Necessity Determinations Across Commercial Insurance Carriers for Prostate Cancer Procedures Search for articles by this author 4-6 minutes Abstract PURPOSE : Variation in commercial insurance coverage may lead to disparity in access to quality cancer care. We evaluated commercial insurance coverage determinations to assess the degree of variation across a national sample. MATERIALS and METHODS : We identified the predominant carrier of commercial insurance in each state based on the 2020 U.S. Government Accounting Office (GAO-21-34) report on insurance. For each state, publicly available medical policies from 1/1/2021 to 1/31/

Prostate Cancer Treatment May Raise Heart Risks

Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial | Radiation Oncology | Full Text

Using health insurance claims data to assess long‐term disease progression in a prostate cancer cohort - Khan - The Prostate - Wiley Online Library

New approaches to targeting epigenetic regulation in prostat... : Current Opinion in Urology

Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States | Prostate Cancer and Prostatic Diseases

The role of PSA density in the MRI pathway for prostate cancer diagnostics | Prostate Cancer and Prostatic Diseases

ASCO 2022: Phase 1b Study of Bavdegalutamide, an Androgen Receptor PROTAC Degrader, Combined with Abiraterone in Patients with Metastatic Prostate Cancer

Bavdegalutamide Showcases Early Activity in Metastatic Castration-Resistant Prostate Cancer

Radiotherapy in Oligometastatic Prostate Cancer - ScienceDirect

A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer - ScienceDirect

Integrating pharmacogenomics data-driven prediction with bulk and single-cell RNAseq to demonstrate the efficacy of an NAMPT inhibitor against aggressive, taxane-resistant, and stem-like cells in lethal prostate cancer | bioRxiv

The role of prophylactic prostatectomy as a primary preventi... : Current Opinion in Urology

Polygenic risk score in prostate cancer : Current Opinion in Urology

Novel germline mutations for active surveillance and imaging... : Current Opinion in Urology

Drugs or Active Surveillance for Low-Risk Prostate Cancer?

Integrative analysis of the MD Anderson Prostate Cancer Patient-Derived Xenograft Series (MDA PCa PDX) | bioRxiv

Optimization of prostate cancer patient lymph node staging via the integration of neutrophil–lymphocyte ratios, platelet–lymphocyte ratios, and 68Ga‐PSMA‐PET‐derived SUVmax values - Wang - The Prostate - Wiley Online Library

Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy - Hartrampf - The Prostate - Wiley Online Library : Background Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is increasingly incorporated in the therapeutic algorithm of patients with metastatic castration-resistant pro... onlinelibrary.wiley.com Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy Philipp E. Hartrampf MD 20-26 minutes 1 INTRODUCTION Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has demonstrated convincing outcome benefits in metastatic castration-resistant prostate cancer (mCRPC), rendering 177 Lu-PSMA as an attractive treatment o

Fast, uncomplicated, and specific: Diagnosis of prostate cancer from blood samples phys.org Fast, uncomplicated, and specific: Diagnosis of prostate cancer from blood samples Science X staff 5-7 minutes Graphical abstract. Credit: Angewandte Chemie International Edition (2022). DOI: 10.1002/anie.202207037 Early detection of prostate cancer, one of the most common types of cancer in men, is often achieved with PSA tests. However, this blood test for prostate-specific antigens gives many false positive results, causing unnecessary biopsies and overtreatment. In the journal Angewandte Chemie International Edition , a Chinese research team now introduces a highly specific, non-invasive alternative to biopsy: the "thermophoretic AND gate operation" assay, abbreviated as Tango, quickly and reli

Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer | Nature

Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer | PLOS ONE

The 28th Annual Prostate Cancer Foundation Scientific Retreat report - Miyahira - The Prostate - Wiley Online Library

Early Salvage RT 'Not Be Early Enough' for Some Prostate Cancers

Prognosis of prostate cancer patients improved -- ScienceDaily

A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent | Clinical Cancer Research | American Association for Cancer Research

Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer | Clinical Cancer Research | American Association for Cancer Research

‘Normal’ cells and ‘cancer’s surprising circular DNA’: Inside Cancer Grand Challenges Part 2 - Cancer Research UK - Cancer news

Cureus | Treatment-Refractory, Castration-Resistant Prostate Cancer With Liver Metastasis: A Promising Modality of Therapy

Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States | Prostate Cancer and Prostatic Diseases

Editor’ summary: A paradigm shift in castration-resistant prostate cancer management | Prostate Cancer and Prostatic Diseases

Fractionation Choice for Elective Lymph Node Radiation Therapy in Prostate Cancer: Slightly More to CHIRP About - International Journal of Radiation Oncology, Biology, Physics

Transperineal Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: a pilot study | Prostate Cancer and Prostatic Diseases

Prostate Cancer: Causes and Risk Factors

Expert wisdom on prostate cancer testing not evident in NHS commissioning guidance | The BMJ

Diagnosing prostate cancer at a curable stage means providing PSA tests to asymptomatic patients | The BMJ

How Realistic Is Radical Prostatectomy Without Prior Biopsy? | MedPage Today

Think You’re at High Risk of Prostate Cancer? Healthy Living Can Slash Odds for Lethal Disease | Cooking with Kathy Man

A novel prognostic model predicting overall survival in patients with metastatic castration‐resistant prostate cancer receiving standard chemotherapy: A multi‐trial cohort analysis - Modonutti - - The Prostate - Wiley Online Library

Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer | Prostate Cancer and Prostatic Diseases : Molecular biomarker tests are developed as diagnostic tools for prostate cancer (PCa) diagnosis. The SelectMDx (MDxHealth, Nijmegen, The Netherlands) test is a urinary-based biomarker test intended to be used to predict presence of high-grade PCa upon biopsy in men with elevated serum prostate-specific antigen (PSA) levels. Previous validation of the SelectMDx test revealed that 53% of the unnecessary biopsies (biopsies indicating no- or GG1 PCa) could be avoided using the SelectMDx test as a decision-tool to select men for prostate biopsy. The objective of this study is to examine the use of the commercially available SelectMDx test under routine, real-life practice. Men that underwent a SelectMDx test between May 2019 and December 2020 and that were originating from countries that perform the SelectMDx test on a regular basis were included in this study, resulting

A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer - ScienceDirect

Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy | Prostate Cancer and Prostatic Diseases

How radiotherapy became a lifesaver – from X-rays to the proton beam - Cancer Research UK - Cancer news

Novel Focal Therapy Yields Low Rate of Serious Prostate Cancers | MedPage Today

Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer | Prostate Cancer and Prostatic Diseases

The evolving clinical use of prostate cancer biomarkers | Prostate Cancer and Prostatic Diseases

Prostate Cancer Cases Are Growing More Serious

6 changes that could lower the risk of developing prostate cancer kevinmd.com 6 changes that could lower the risk of developing prostate cancer Kevin 5-6 minutes After skin cancer, prostate cancer is the most common type of cancer diagnosed in people with a prostate. Some risk factors associated with prostate cancer can’t be mitigated. Those factors include older age, a family history of prostate cancer, and race (Black men have double the risk of developing prostate cancer compared to white men). There are, however, lifestyle changes that men can make that may reduce prostate cancer risk. Diet choices, activity level, and maintaining a healthy weight have all been found by researchers to be associated with a decrease in prostate cancer risk. Lifestyle changes to reduce prostate cancer risk These six changes can help men be healthier overall and manage their risk of developing

Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics | Prostate Cancer and Prostatic Diseases

Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and External Beam Radiation - ScienceDirect : External beam radiation therapy (EBRT) to oligometastases may improve outcomes in patients with oligometastatic hormone-sensitive prostate cancer (oHS…

Transperineal vs Transrectal Prostate Biopsy: Is One Better?

Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes | Prostate Cancer and Prostatic Diseases

Positive Margins Post-Prostatectomy: Does Size Matter?

Bundaberg grandfather is the first participant for global prostate cancer trial | ABC News - YouTube